- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acromegaly Functional carcinoid tumour. Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET).
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Lanreotide – March 2026
Injection 60 mg (as acetate) in single dose pre-filled syringe, Injection 90 mg (as acetate) in single dose pre-filled syringe, Injection 120 mg (as acetate) in single dose pre-filled syringe
Last updated
11 March 2026